Progyny, Inc.

PGNY Healthcare Healthcare Plans

Progyny, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 5.30%, EPS grew 80.0% and free cash flow fell 12.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

26.86 0.60 −2.18%
Market cap
$2.1B
P/E
27.7×
Fwd P/E
19.9×
Dividend yield
—
F-score
8/9
Altman Z
8.89
Beneish M
−3.45
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
29.72 20.96 37.22 32.61

+8 more quarters

P/S ratio
1.72 1.06 1.71 1.46
P/FCF ratio
12.63 7.45 11.47 9.57
P/Operating CF
44.69 29.90 40.58 36.53
P/B ratio
4.97 3.13 4.26 3.31
EV/Sales
1.54 0.89 1.47 1.19
EV/EBITDA
17.15 11.33 20.99 16.14
EV/FCF
11.33 6.26 9.88 7.81
Current Ratio
2.14 2.13 2.73 2.96
Net Debt/EBITDA
(5.69) (6.11) (18.22) (15.44)
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
3.36% 4.77% 2.69% 3.07%
Free Cash Flow Yield
7.92% 13.42% 8.72% 10.45%
Free Cash Flow per Share
0.57 0.49 0.57 0.53
Book value per Share
5.80 5.43 6.02 6.51
Free Cash Flow
44.21 39.60 48.59 45.99
EV/EBIT
18.03 11.96 22.21 17.60
Other line items

Show all line items

Columns are period end dates